Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies
Authors
Keywords
-
Journal
Nature Reviews Endocrinology
Volume 16, Issue 11, Pages 629-641
Publisher
Springer Science and Business Media LLC
Online
2020-08-24
DOI
10.1038/s41574-020-0398-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- State-of-the-Art Strategies for Targeting RET-Dependent Cancers
- (2020) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
- (2020) Wenting Zhang et al. Frontiers in Immunology
- PD-1 Blockade in Anaplastic Thyroid Carcinoma
- (2020) Jaume Capdevila et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Immune Profiling of Medullary Thyroid Cancer
- (2020) Nikita Pozdeyev et al. THYROID
- A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer
- (2019) Shunji Takahashi et al. Future Oncology
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
- (2019) Janice M. Mehnert et al. BMC CANCER
- Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).
- (2019) Eric Jeffrey Sherman et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy
- (2019) Christian M. Schürch et al. THYROID
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- The Association between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma
- (2019) Xiao Shi et al. THYROID
- Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma
- (2019) Jennifer Rui Wang et al. THYROID
- Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy
- (2019) Yogindra Vedvyas et al. Scientific Reports
- Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
- (2019) Georgina V Long et al. LANCET ONCOLOGY
- BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts
- (2019) Daofu Feng et al. ONCOGENE
- ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome
- (2019) Claire Y Oh et al. Cancer Immunology Research
- A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer
- (2019) Ashish V. Chintakuntlawar et al. THYROID
- Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
- (2018) Nikita Pozdeyev et al. CLINICAL CANCER RESEARCH
- PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma
- (2018) Matthew W. Rosenbaum et al. ENDOCRINE PATHOLOGY
- Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma
- (2018) Joshua R. Veatch et al. JOURNAL OF CLINICAL INVESTIGATION
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
- (2018) Nikolaos Zacharakis et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
- (2018) Natalie J. Neubert et al. Science Translational Medicine
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
- (2018) Priyanka C. Iyer et al. Journal for ImmunoTherapy of Cancer
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- (2018) Jun Gong et al. Journal for ImmunoTherapy of Cancer
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
- (2018) André Kahles et al. CANCER CELL
- Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers
- (2018) Jeffrey A. Knauf et al. JOURNAL OF CLINICAL INVESTIGATION
- 1824PLenvatinib and pembrolizumab as save and effective combination treatment in 8 patients with metastasized anaplastic (ATC) or poorly differentiated thyroid carcinoma (PDTC)
- (2018) C Dierks et al. ANNALS OF ONCOLOGY
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- (2018) Noelle Frey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
- (2018) Viswanath Gunda et al. BRITISH JOURNAL OF CANCER
- The Reciprocity between Radiotherapy and Cancer Immunotherapy
- (2018) Yifan Wang et al. CLINICAL CANCER RESEARCH
- Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
- (2018) Viswanath Gunda et al. INTERNATIONAL JOURNAL OF CANCER
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- Mouse Models for Cancer Immunotherapy Research
- (2018) Brian Olson et al. Cancer Discovery
- Very low expression of PD-L1 in medullary thyroid carcinoma
- (2017) Massimo Bongiovanni et al. ENDOCRINE-RELATED CANCER
- Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013
- (2017) Hyeyeun Lim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study
- (2017) Ashish V. Chintakuntlawar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
- (2017) Mohammad Rashidian et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
- (2017) Revathi Kollipara et al. ONCOLOGIST
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity
- (2017) Karla R. Wiehagen et al. Cancer Immunology Research
- 4-1BB–Enhanced Expansion of CD8 + TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8 + T Cells
- (2017) Michiko Harao et al. Cancer Immunology Research
- Leveraging the immune system to treat advanced thyroid cancers
- (2017) Jena D French et al. Lancet Diabetes & Endocrinology
- Rejection versus escape: the tumor MHC dilemma
- (2016) Federico Garrido et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600Eand Pten Loss
- (2016) Lee Ann Jolly et al. CANCER RESEARCH
- Epitope-specific antitumor immunity suppresses tumor spread in papillary thyroid cancer
- (2016) Margret Ehlers et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer
- (2016) Jill J. Bastman et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL INVESTIGATION
- A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
- (2016) Cristina Romei et al. Nature Reviews Endocrinology
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent
- (2016) Trevor E. Angell et al. THYROID
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
- (2016) Bryan R. Haugen et al. THYROID
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
- (2016) Eran Brauner et al. Oncotarget
- Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants
- (2016) Subrata Chowdhury et al. Oncotarget
- Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy
- (2015) Sander Kelderman et al. CANCER CELL
- Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review
- (2015) Ana Albero et al. ENDOCRINE-RELATED CANCER
- Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
- (2015) Douglas Marvel et al. JOURNAL OF CLINICAL INVESTIGATION
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
- (2015) Samuel A. Wells et al. THYROID
- PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer
- (2015) J. J. Severson et al. Cancer Immunology Research
- BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma
- (2015) S. D. Bradley et al. Cancer Immunology Research
- Combined BRAFV600E- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer
- (2015) Pierre Vanden Borre et al. Oncotarget
- MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro
- (2014) T. E. Angell et al. CLINICAL CANCER RESEARCH
- Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
- (2014) Jessica Ann Chacon et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Complexity and challenges in defining myeloid-derived suppressor cells
- (2014) Vera Damuzzo et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
- (2014) D. G. McFadden et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
- (2014) E. Tran et al. SCIENCE
- BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration
- (2014) Trevor E. Angell et al. THYROID
- Definition and management of radioactive iodine-refractory differentiated thyroid cancer
- (2014) Martin Schlumberger et al. Lancet Diabetes & Endocrinology
- Control of the Immune Response by Pro-Angiogenic Factors
- (2014) Thibault Voron et al. Frontiers in Oncology
- Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
- (2013) Marijo Bilusic et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
- (2013) Marina N. Nikiforova et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cabozantinib in Progressive Medullary Thyroid Cancer
- (2013) Rossella Elisei et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression
- (2013) Mabel Ryder et al. PLoS One
- The Next Generation of Orthotopic Thyroid Cancer Models: Immunocompetent Orthotopic Mouse Models of BRAFV600E-Positive Papillary and Anaplastic Thyroid Carcinoma
- (2013) Pierre Vanden Borre et al. THYROID
- Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma
- (2013) Julie A. Sosa et al. THYROID
- Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells
- (2013) Amandine Legat et al. Frontiers in Immunology
- Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer
- (2012) Lucas Leite Cunha et al. ENDOCRINE-RELATED CANCER
- A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
- (2012) Keith C. Bible et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phenotypical Analysis of Lymphocytes with Suppressive and Regulatory Properties (Tregs) and NK Cells in the Papillary Carcinoma of Thyroid
- (2012) Foteini Gogali et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Programmed Death-1+T Cells and Regulatory T Cells Are Enriched in Tumor-Involved Lymph Nodes and Associated with Aggressive Features in Papillary Thyroid Cancer
- (2012) Jena D. French et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Advances in the follow-up of differentiated or medullary thyroid cancer
- (2012) Rossella Elisei et al. Nature Reviews Endocrinology
- Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
- (2012) Lukas Baitsch et al. PLoS One
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- Density of Tumor-Associated Macrophages Correlates with Lymph Node Metastasis in Papillary Thyroid Carcinoma
- (2012) Wei Qing et al. THYROID
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
- (2012) Robert C. Smallridge et al. THYROID
- Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the Thyroid
- (2012) Panayiotis Savvides et al. THYROID
- Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches
- (2011) Pamela Jo Harris et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Control of macrophage lineage populations by CSF-1 receptor and GM-CSF in homeostasis and inflammation
- (2011) Jason C Lenzo et al. IMMUNOLOGY AND CELL BIOLOGY
- Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes
- (2011) Rafael Carretero et al. INTERNATIONAL JOURNAL OF CANCER
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Associated Macrophages (TAMs) Form an Interconnected Cellular Supportive Network in Anaplastic Thyroid Carcinoma
- (2011) Bernard Caillou et al. PLoS One
- Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice
- (2011) A. T. Franco et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Tumor-Associated Lymphocytes and Increased FoxP3+Regulatory T Cell Frequency Correlate with More Aggressive Papillary Thyroid Cancer
- (2010) Jena D. French et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
- (2010) Maria R Parkhurst et al. MOLECULAR THERAPY
- Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas
- (2009) M M Moura et al. BRITISH JOURNAL OF CANCER
- Gene Expression of Differentiation- and Dedifferentiation Markers in Normal and Malignant Human Thyroid Tissues
- (2009) C. Hoang-Vu et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma
- (2009) Bachleitner-Hofmann ONCOLOGY REPORTS
- Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer
- (2008) M. Ryder et al. ENDOCRINE-RELATED CANCER
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now